GSK licenses Genmab's HuMax-DC20 for $2.1B
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
GlaxoSmithKline |
Genmab |
$2.1B licensing deal |
The deals is for Genmab's HuMax-CD20 antibody for leukemia. |
|
Amgen |
Cytokinetics |
$675M development deal |
The deal covers CK-1827452, which triggers a protein that causes the heart to contract as it pumps blood. |
|
Forest Laboratories |
Cerexa |
$480M buyout |
Forest gains development and marketing rights for three antibiotics, including one--ceftaroline acetate--which is poised to begin a late-stage trial for skin infections. |
|
Vectura Group |
Unnamed company |
$63M development pact |
Vectura has been working on a copycat version of Glaxo's best selling asthma drug Advair, which loses patent protection in 2010. |
|
Bristol-Myers Squibb |
Exelixis |
$60M development deal |
Exelixis is responsible for selecting small molecule drugs for specific targets while BMS has the right to choose up to three candidates for three targets. |
|
GlaxoSmithKline |
Praecis Pharmaceuticals |
$54.8 buyout |
Praecis will provide chemical-synthesis and screening technology that will GSK will use with it's own discovery capabilities. |
|
Genentech |
Exelixis |
$40M development pact |
Genentech and Exelixis have agreed to a global development pact for XL-518, an MEK-inhibitor for tumors. |
|
Genentech |
Altus |
$30M development deal |
The pact covers ALTU-238, an experimental human growth hormone being developed as a once-weekly therapy. |
|
Centocor |
FivePrime Therapeutics |
$15M collaboration pact |
FivePrime Therapeutics will work with Centocor Research on the development of new therapies for osteoarthritis and pulmonary fibrosis. |
|
PerkinElmer |
Euroscreen Products |
Buyout |
Euroscreen markets products to laboratories engaged in drug discovery work. This is ElmerPerkin's seventh acquisition of the year. |
|
Otsuka Pharmaceutical |
Bristol-Myers Squibb |
Licensing deal |
Otsuka Pharmaceutical has licensed the Japanese rights to Bristol-Myers Squibb's saxagliptin, being studied for the treatment of Type 2 diabetes. |
|
Schering-Plough |
Valeant Pharmaceuticals and Metabasis Technologies |
Licensing deal |
Schering-Plough has licensed the experimental pradefovir for chronic hepatitis B. Valeant licensed the drug from Metabasis six years ago. |